BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Dyax Corp. 

55 Network Drive

Burlington  Massachusetts  01803  U.S.A.
Phone: 617-225-2500 Fax: 617-225-2501


SEARCH JOBS

View Clinical Trials from BioPharm Insight


Founded in 1995, Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key areas of focus are the KALBITOR® (ecallantide) business and the Angioedema Portfolio, as well as the Licensing and Funded Research Program (LFRP).

Dyax discovered and developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside of the United States, the Company has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and is evaluating opportunities in others. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, Australia and New Zealand. Dyax is also exploring other potential indications for KALBITOR, either alone or through collaborations.

The Company is expanding its portfolio for the treatment of angioedemas by identifying diagnostic strategies to assist in the differentiation between histamine-mediated and plasma kallikrein (bradykinin) mediated (PKM) angioedema, and developing a fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, which could be a candidate to prophylactically treat PKM angioedemas.

KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 11 product candidates in various stages of clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.


 Key Statistics


Email: ir@dyax.com
Ownership:

Web Site: Dyax Corp.
Employees: 120
Symbol: DYAX
 



Industry
Biotechnology


Collaborations

CMIC Co., Ltd.  Ecallantide in HAE and other angioedemas indications

Sigma-Tau Group  Ecallantide in HAE and other therapeutic indications

Eli Lilly and Company  Antibody phage display

Amgen  Antibody phage display

Merrimack Pharmaceuticals Inc.  Antibody phage display

Sanofi-Aventis (New Jersey)  Antibody phage display

Biogen Idec, Inc. (Massachusetts)  Antibody phage display

Genzyme Corporation  Hereditary Angioedema





 Company News
Dyax Corp. (DYAX) Announces Publication Of Scientific Data For DX-2930 In Peer-Reviewed Journals 7/23/2014 12:10:45 PM
Dyax Corp. (DYAX) To Host Second Quarter 2014 Earnings Call And Webcast 7/15/2014 10:11:44 AM
Dyax Corp. (DYAX) To Participate In The 2014 Wells Fargo Healthcare Conference 6/10/2014 6:50:25 AM
Dyax Corp. (DYAX) To Participate In The Jefferies and Co. Global Healthcare Conference 5/29/2014 7:54:44 AM
Dyax Corp. (DYAX) Announces Dosing Of First Subject In Phase 1b Trial Of DX-2930 In Patients With Hereditary Angioedema 5/28/2014 8:50:24 AM
Dyax Corp. (DYAX) Announces First Quarter 2014 Financial Results 5/1/2014 2:09:44 PM
Dyax Corp. (DYAX) To Host First Quarter 2014 Earnings Call And Webcast 4/17/2014 6:56:35 AM
Dyax Corp. (DYAX) Announces Appointment Of Todd Bazemore As Chief Commercial Officer 4/16/2014 6:52:00 AM
Dyax Corp. (DYAX) Receives FDA Approval To Expand Use Of KALBITOR® (Ecallantide) For The Treatment Of Acute Attacks Of Hereditary Angioedema To Patients 12 Years Of Age And Older 4/4/2014 8:13:31 AM
Dyax Corp. (DYAX) Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares 3/26/2014 10:05:26 AM
12345678910...